Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort.
Fiche publication
Date publication
août 2018
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle, Dr MENNECIER Bertrand, Pr WESTEEL Virginie
Tous les auteurs :
Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazieres J, Besse B, Girard N
Lien Pubmed
Résumé
Thymic epithelial tumors (TET) are rare malignancies that may be aggressive and difficult to treat. In the advanced setting, systemic treatments may be delivered as primary therapy before surgery or definitive radiotherapy, as exclusive treatment when no focal treatment is feasible, or in the setting of recurrences. RYTHMIC is the nationwide network for TET in France. The objective of the study was to describe the modalities and analyze the efficacy of systemic treatments for patients with advanced TET included in the RYTHMIC prospective database hosted by the French Thoracic Cancer Intergroup (IFCT).
Mots clés
Chemotherapy, Network, Recurrence, Thymic Carcinoma, Thymoma
Référence
J Thorac Oncol. 2018 Aug 20;: